Evaluation of the use of piperacillin/tazobactam (Tazocin®) at Hamad General Hospital, Qatar: are there unjustified prescriptions?

من ويكيتعمر
اذهب إلى: تصفح، ابحث

Evaluation of the use of piperacillin/tazobactam (Tazocin®) at Hamad General Hospital, Qatar: are there unjustified prescriptions?

Infect Drug Resist. 2012; 5: 17–21.

Published online 2012 Jan 13. doi: 10.2147/IDR.S27965

PMCID: PMC3269129

Fahmi Yousef Khan,1 Abdelhaleem Elhiday,1 Imran Fahmi Khudair,2 Hind Yousef,3 Aisha Hussein Omran,4 Samer Hytham Alsamman,1 and Maha Elhamid2

Abstract[عدل]

Objectives[عدل]

The aim of this study was to evaluate the appropriateness of piperacillin/tazobactam (Tazocin®; Pfizer, New York, NY) usage in our hospital.

Subjects and methods[عدل]

This retrospective study was designed to involve all patients admitted to Hamad General Hospital and prescribed piperacillin/tazobactam as an empiric therapy from January 1 to March 31, 2008. The medical records of such patients were retrospectively reviewed and studied.

Results[عدل]

During this period, 610 prescriptions were ordered for 596 patients. The main indication for initiation of Tazocin was sepsis (207/610; 34%). The overall rate of appropriateness of empirical therapy was 348/610 (57%). Most of the inappropriate prescriptions were in cases of aspiration pneumonia and abdominal infections, with inappropriate prescriptions found mostly in surgical wards (86%) and the surgical intensive care unit (66.7%). Septic work-up results showed positive cultures in 57% (345/610) of cases. There were 198/254 prescriptions (78%) where antibiotics were changed according to the sensitivity data to narrow-spectrum antimicrobials. In 56/254 (22%) cases, pathogens were susceptible to narrow-spectrum antibiotics even though piperacillin/tazobactam was continued.

Conclusion[عدل]

Our study showed that there was an injudicious use of piperacillin/tazobactam at our hospital, evidenced by the significant number of inappropriate empiric prescriptions and inappropriate drug modifications, based on the results of microbial cultures and antibiograms.

Keywords: piperacillin/tazobactam, empiric therapy, appropriate use, broad-spectrum antibiotics

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269129/